Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Fampyra 10mg prolonged release tablets2件: Dalfampridine,
Manganese citrate		1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
2Mezavant Gastro-resistant, prolonged release tablets2件: Manganese citrate,
Mesalazine		1件: D00377 --1件: 97
3Mezavant XL 1200 mg gastro-resistant prolonged release tablets2件: Manganese citrate,
Mesalazine		1件: D00377 --1件: 97
4Mezavant XL 1200 mg gastro-resistant, prolonged release tablets2件: Manganese citrate,
Mesalazine		1件: D00377 --1件: 97
5Mezavant XL 1200 mg gastro-resistant, prolonged release tablets.2件: Manganese citrate,
Mesalazine		1件: D00377 --1件: 97
6Mezavant XL 1200mg gastro-resistant, prolonged release tablets2件: Manganese citrate,
Mesalazine		1件: D00377 --1件: 97
7Mezavant XL Gastro-resistant, prolonged release tablets2件: Manganese citrate,
Mesalazine		1件: D00377 --1件: 97
8Oxycodone naloxone prolonged release tablets2件: Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
9Oxycodone/Naloxone Prolonged Release tablets2件: Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
10Oxycodone/naloxone prolonged release tablets 10 mg /5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
11Oxycodone/naloxone prolonged release tablets 10/5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
12Oxycodone/naloxone prolonged release tablets 20 mg /10 mg3件: Manganese citrate,
Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
13Oxycodone/naloxone prolonged release tablets 20/10 mg3件: Manganese citrate,
Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
14Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
15Oxycodone/naloxone prolonged release tablets 5/2.5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		2件: D05312 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
16Prolonged release tablet1件: Manganese citrate---1件: 6
17Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
18Xeljanz® 11mg Prolonged Release Tablet2件: Manganese citrate,
Tofacitinib		1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46